Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765669908> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2765669908 abstract "Amyloid-PET imaging with visual analysis is approved by the FDA for Alzheimer's disease (AD) diagnosis, but is technically complex, costly, and a radiation burden to patients. An alternative is measurement of cerebrospinal fluid (CSF) biomarkers β-Amyloid(1–42) (Aβ42), total tau (tTau), and phosphorylated tau (181P) (pTau), for which Roche Diagnostics is developing electrochemiluminescence immunoassays (Elecsys®). Using data from the BioFINDER and ADNI cohorts, we assessed whether the Elecsys® CSF biomarkers could reliably distinguish amyloid-PET-positive from -negative patients. We also compared visual-read amyloid-PET image analysis vs. the semi-quantitative, standardized uptake value ratios (SUVR) method. Patients had banked CSF samples and amyloid-PET images, as well as subjective cognitive decline or mild cognitive impairment (BioFINDER, N=277; 18Fflutemetamol) or mild cognitive impairment or subjective memory complaints, or AD (ADNI, N≈650; 18Fflorbetapir). Three independent readers, blinded to clinical data, visually evaluated amyloid-PET scans; amyloid-PET positivity was determined by majority assessment. Intra-reader reliability was determined based on re-ratings of approximately 10% of randomly selected images from available PET scans. Inter-reader reliability was also assessed. SUVRs were calculated in a standardized cortical region-of-interest using whole cerebellum as the reference region. CSF samples were analyzed using Elecsys® immunoassays for Aβ42, tTau, and pTau. Data from both ADNI and BioFINDER cohorts will be presented. For BioFINDER, intra-reader reliability based on average positive agreement (APA) and average negative agreement (ANA) was >90%. Inter-reader reliability gave an APA >80% and ANA >90%. Cut-off values for Aβ42, pTau/Aβ42, and tTau/Aβ42 were defined based on visual-read amyloid-PET positivity. The associated positive (PPA) and negative percentage agreements (NPA) at the cut-off value were 91% and 72% for Aβ42, and 91% and 89% for both pTau/Aβ42 and tTau/Aβ42, respectively. Higher concordance could be achieved with reference SUVR. We present a method to determine cut-off values of Elecsys® CSF immunoassays based on visual-read amyloid-PET positivity. The Elecsys® CSF immunoassays demonstrated excellent ability to predict amyloid-PET positivity, which was further improved by using tTau/Aβ42 and pTau/Aβ42 ratios compared to Aβ42 alone." @default.
- W2765669908 created "2017-11-10" @default.
- W2765669908 creator A5004436960 @default.
- W2765669908 creator A5023136222 @default.
- W2765669908 creator A5025313057 @default.
- W2765669908 creator A5029433626 @default.
- W2765669908 creator A5037230816 @default.
- W2765669908 creator A5046772800 @default.
- W2765669908 creator A5057166147 @default.
- W2765669908 creator A5066503440 @default.
- W2765669908 creator A5081300101 @default.
- W2765669908 creator A5084921557 @default.
- W2765669908 date "2017-07-01" @default.
- W2765669908 modified "2023-10-16" @default.
- W2765669908 title "[O1–05–05]: AMYLOID‐PET CONCORDANCE OF ELECSYS® CSF BIOMARKER IMMUNOASSAYS FOR ALZHEIMER's DISEASE" @default.
- W2765669908 doi "https://doi.org/10.1016/j.jalz.2017.07.062" @default.
- W2765669908 hasPublicationYear "2017" @default.
- W2765669908 type Work @default.
- W2765669908 sameAs 2765669908 @default.
- W2765669908 citedByCount "10" @default.
- W2765669908 countsByYear W27656699082018 @default.
- W2765669908 countsByYear W27656699082019 @default.
- W2765669908 countsByYear W27656699082020 @default.
- W2765669908 countsByYear W27656699082021 @default.
- W2765669908 countsByYear W27656699082022 @default.
- W2765669908 crossrefType "journal-article" @default.
- W2765669908 hasAuthorship W2765669908A5004436960 @default.
- W2765669908 hasAuthorship W2765669908A5023136222 @default.
- W2765669908 hasAuthorship W2765669908A5025313057 @default.
- W2765669908 hasAuthorship W2765669908A5029433626 @default.
- W2765669908 hasAuthorship W2765669908A5037230816 @default.
- W2765669908 hasAuthorship W2765669908A5046772800 @default.
- W2765669908 hasAuthorship W2765669908A5057166147 @default.
- W2765669908 hasAuthorship W2765669908A5066503440 @default.
- W2765669908 hasAuthorship W2765669908A5081300101 @default.
- W2765669908 hasAuthorship W2765669908A5084921557 @default.
- W2765669908 hasBestOaLocation W27656699081 @default.
- W2765669908 hasConcept C126322002 @default.
- W2765669908 hasConcept C142724271 @default.
- W2765669908 hasConcept C143998085 @default.
- W2765669908 hasConcept C15744967 @default.
- W2765669908 hasConcept C160798450 @default.
- W2765669908 hasConcept C185592680 @default.
- W2765669908 hasConcept C2777633098 @default.
- W2765669908 hasConcept C2779134260 @default.
- W2765669908 hasConcept C2779483572 @default.
- W2765669908 hasConcept C2779651940 @default.
- W2765669908 hasConcept C2781197716 @default.
- W2765669908 hasConcept C2984915365 @default.
- W2765669908 hasConcept C2989005 @default.
- W2765669908 hasConcept C55493867 @default.
- W2765669908 hasConcept C71924100 @default.
- W2765669908 hasConceptScore W2765669908C126322002 @default.
- W2765669908 hasConceptScore W2765669908C142724271 @default.
- W2765669908 hasConceptScore W2765669908C143998085 @default.
- W2765669908 hasConceptScore W2765669908C15744967 @default.
- W2765669908 hasConceptScore W2765669908C160798450 @default.
- W2765669908 hasConceptScore W2765669908C185592680 @default.
- W2765669908 hasConceptScore W2765669908C2777633098 @default.
- W2765669908 hasConceptScore W2765669908C2779134260 @default.
- W2765669908 hasConceptScore W2765669908C2779483572 @default.
- W2765669908 hasConceptScore W2765669908C2779651940 @default.
- W2765669908 hasConceptScore W2765669908C2781197716 @default.
- W2765669908 hasConceptScore W2765669908C2984915365 @default.
- W2765669908 hasConceptScore W2765669908C2989005 @default.
- W2765669908 hasConceptScore W2765669908C55493867 @default.
- W2765669908 hasConceptScore W2765669908C71924100 @default.
- W2765669908 hasIssue "7S_Part_4" @default.
- W2765669908 hasLocation W27656699081 @default.
- W2765669908 hasOpenAccess W2765669908 @default.
- W2765669908 hasPrimaryLocation W27656699081 @default.
- W2765669908 hasRelatedWork W1972349970 @default.
- W2765669908 hasRelatedWork W1986398611 @default.
- W2765669908 hasRelatedWork W2548509799 @default.
- W2765669908 hasRelatedWork W2748952813 @default.
- W2765669908 hasRelatedWork W2755459893 @default.
- W2765669908 hasRelatedWork W2788265422 @default.
- W2765669908 hasRelatedWork W2804922289 @default.
- W2765669908 hasRelatedWork W2899084033 @default.
- W2765669908 hasRelatedWork W4312389194 @default.
- W2765669908 hasRelatedWork W4321003452 @default.
- W2765669908 hasVolume "13" @default.
- W2765669908 isParatext "false" @default.
- W2765669908 isRetracted "false" @default.
- W2765669908 magId "2765669908" @default.
- W2765669908 workType "article" @default.